Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719635 | 0.91 | HDAC1 (0.71) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL719628 | 0.90 | HDAC1 (0.60) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL719909 | 0.89 | HDAC3 (0.56) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL718534 | 0.87 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL718369 | 0.87 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL719663 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL721327 | 0.86 | HDAC1 (0.56) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL718972 | 0.84 | HDAC3 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL721483 | 0.84 | HDAC3 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL719842 | 0.83 | HDAC1 (0.81) | HDAC1HDAC2HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | claimed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | claimed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | claimed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | claimed |
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381196-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-07-16 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987468-B2 | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE(TGEN (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100045-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053188-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | HDAC1 11/4885HDAC2 15/4885HDAC8 8/4885 |
| US-20150196559-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HYDROXAMIC ACID DERIVATIVES | HDAC5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC4 | HDAC1 11/4885HDAC2 15/4885HDAC8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.